Navigation Links
Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
Date:2/25/2011

ts statements or its pleadings that undermines the safety and efficacy of Auralgan as a treatment for ear pain and inflammation."

At this time the government's claims are only allegations in a legal proceeding.  Until a court makes a determination on this issue, it remains legally unresolved whether Auralgan qualifies as a "new drug" product.  

Recently, FDA has begun to take actions against classes of products that it believes should not be categorized as "old drugs" and instead should be regulated as "new drugs".  Unlike previous actions, FDA did not take action against both Auralgan and its generic substitutes, but instead, has solely focused its actions on Auralgan.  Currently, Auralgan represents 3% of the market for this class of drug products, with generic substitutes accounting for the other 97%.  FDA has not announced any action against any of these generic competitors or explained whether it intends to take any action against these products in the future.

History of Auralgan

Auralgan, is a solution of antipyrine and benzocaine and has been marketed in the United States since 1947 as a treatment for ear pain and inflammation associated with acute otitis media ("AOM").  

When Deston acquired the rights to Auralgan in 2006, this product and other generic equivalents had been marketed for over fifty years.  During this fifty year period, FDA had never taken enforcement action against any manufacturer for selling these types of drug products as unapproved "new drugs".  FDA's last official statement regarding the regulatory status of Auralgan occurred in 1981 when the Agency's Assistant to the Director, Division of Drug Labeling Compliance said that the Agency had not made a determination whether Auralgan qualified as a "new drug."

During this fifty year period of marketing, Auralgan was the subject of clinical trials supporting its use as safe and effective.  Additio
'/>"/>

SOURCE Deston Therapeutics LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Zacks.com announces the list of stocks featured in ... discuss the latest news and events impacting stocks and the ... (Nasdaq: BIIB - Free Report ), Gilead (Nasdaq: ... - Free Report ), AbbVie (NYSE: ABBV - Free ... ). Today, Zacks is promoting its ,Buy, stock ...
(Date:7/31/2014)... July 31, 2014 Vermillion, Inc. (NASDAQ: VRML), a ... will hold a conference call on Thursday, August 14, 2014, ... second quarter ended June 30, 2014. Financial results will be ... Vermillion,s Chairman, President and CEO James LaFrance ... period. Date: Thursday, August 14, 2014 Time: 4:30 ...
(Date:7/31/2014)... , July 31, 2014 TB Alliance, ... developing better, faster and affordable treatments, announced the ... Vice President, External Affairs. Mr. Brock comes to ... of Major Donor Relations for WWF International (formerly ... role, Mr. Brock will guide the TB Alliance,s ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... 1 The Michael J. Fox Foundation for ... to $6.5 million in total funding available under ... solutions to some of the most difficult hurdles ... PD.The Critical Challenges funding opportunities focus research efforts ...
... 31 Successful and seamless completion of clinical trial ... market research, an effective recruitment strategy, and project management ... Liz Moench notes: "This is achievable when clinical trial ... adds, "We had great team chemistry with the study ...
Cached Medicine Technology:Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease 2Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinson's Disease 3Major Restless Legs Study Completes Enrollment With Support From MediciGlobal 2
(Date:7/31/2014)... 31, 2014 The 2013 edition ... about chemical listings, appellate decisions, litigation and settlement ... affect compliance with California's Proposition 65. , The ... law, regulations, history and trends impacting California's Proposition ... installment of the series which adds approximately 200 ...
(Date:7/31/2014)... (August 1, 2014) If you have asthma, you may ... to help you recognize and respond to changes and understand ... you,re in the green zone, you,re doing well, yellow means ... means you require urgent care. New guidelines are now available ... zone, back into green and away from the red zone. ...
(Date:7/31/2014)... Developer Jamestown, L.P., has been using ... City Market project in Atlanta’s Old Fourth Ward, which ... building into best-in-class office, housing, and retail spaces. As ... with their construction webcam service to assess how it ... construction camera for monitoring and documentation purposes, ...
(Date:7/31/2014)... Hoping to attract new customers who are ... , NutriGold is ready to ship out free samples of ... advantage of this offer fast and easy: http://www.nutrigold.com/Free-Samples ... at NutriGold, "We know that every time customers purchase one ... precious asset: their own health or the health of a ...
(Date:7/31/2014)... has announced that they are now offering a new ... Review of Sexual Satisfaction . The course is ... Clinical and Health Psychology. , This CE course has ... accurate information about sexual satisfaction so that healthcare professionals ... provides a systematic review of 197 research publications in ...
Breaking Medicine News(10 mins):Health News:Save 25% on the Proposition 65 Handbook - 2013 Edition Through August 31 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 2Health News:OxBlue Construction Webcam Proves Valuable Tool for Developer, Consumers on Historic Ponce City Market Project 3Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3
... ... with GFK Custom Research North America, selected Warady & Davis LLP, Certified Public Accountants ... Chicago based on its innovative internships, "W&D University" training program, flexible scheduling, great team ... ...
... Oct. 28 The Board of Directors of Healthcare Trust ... of October, November, and December 2009. These distributions will ... during such month and will equal a 7.25% annualized rate ... The payment date for each of the daily distributions for ...
... , DENVER, Oct. 28 Many medical practices are ... are making basic business mistakes, according to Andrew Graham, ... the top reasons practices struggle, said Graham. , ... needs to include goals for revenue generation, customer service, ...
... for the third quarter ended September 30, 2009. Financial highlights from continuing operations for the third quarter of 2009 compared to ... in millions, except per share amounts), ... ... ...
... supply and demand starting to close, U.S. officials say, ... reported Wednesday the addition of another million doses H1N1 ... 23.2 million doses. , "We know people are ... now," Janet Napolitano, secretary of the U.S. Department of ...
... Application provides ... ... Harvard Health Publications Division of Harvard Medical School has launched an iPhone application focused ... knowledge of the experts at Harvard Medical School along with its long-standing expertise in publishing ...
Cached Medicine News:Health News:Warady & Davis LLP Named One of 'Top 50 Employers for Generation Y Chicago' 2Health News:Warady & Davis LLP Named One of 'Top 50 Employers for Generation Y Chicago' 3Health News:Board of Directors Declares Cash Distributions 2Health News:The Top 10 Business Mistakes Made By Physician Practices 2Health News:Carriage Services Announces Third Quarter 2009 Results 2Health News:Carriage Services Announces Third Quarter 2009 Results 3Health News:Carriage Services Announces Third Quarter 2009 Results 4Health News:Carriage Services Announces Third Quarter 2009 Results 5Health News:Carriage Services Announces Third Quarter 2009 Results 6Health News:Carriage Services Announces Third Quarter 2009 Results 7Health News:Carriage Services Announces Third Quarter 2009 Results 8Health News:Carriage Services Announces Third Quarter 2009 Results 9Health News:Carriage Services Announces Third Quarter 2009 Results 10Health News:Carriage Services Announces Third Quarter 2009 Results 11Health News:Carriage Services Announces Third Quarter 2009 Results 12Health News:Carriage Services Announces Third Quarter 2009 Results 13Health News:Carriage Services Announces Third Quarter 2009 Results 14Health News:Carriage Services Announces Third Quarter 2009 Results 15Health News:Carriage Services Announces Third Quarter 2009 Results 16Health News:Carriage Services Announces Third Quarter 2009 Results 17Health News:Carriage Services Announces Third Quarter 2009 Results 18Health News:Carriage Services Announces Third Quarter 2009 Results 19Health News:Carriage Services Announces Third Quarter 2009 Results 20Health News:1 Million More Doses of Swine Flu Vaccine on Hand 2Health News:Harvard Health Publications Launches H1N1 Flu iPhone Application 2Health News:Harvard Health Publications Launches H1N1 Flu iPhone Application 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: